Last Updated on November 11, 2024 by The Health Master
Biotechnology company Biocon has informed that the US Food and Drug Administration (USFDA) concluded a surveillance and pre-approval inspection of Biocon Pharma Limited Oral Solid Dosage formulations manufacturing facility at Bengaluru.
The inspection was conducted at Biocon Pharma’s Oral Solid Dosage formulations manufacturing facility in Bengaluru on June 2.
USFDA completes inspection at Biocon on June 2 and issued ‘no observations’ on completion.
Last month, the USFDA concluded a pre-approval inspection for Site 3, Biocon, located at Hyderabad with no observations. The inspection was carried out on May 19.
USFDA completes inspection of Zydus Lifesciences with zero observation
USFDA issues Form 483 with 4 observations to Aurobindo Pharma
USFDA issues Form 483 with zero observations to Pharma MSMEs: Gujarat
USFDA issues Form 483 with 3 observation to Zydus, Ahmedabad
USFDA issues Form 483 with zero observation to Piramal
USFDA issues Form 483 with 10 observations to Lupin, Pithampur
USFDA completes inspection of Zydus Lifesciences with zero observation
Machines stolen from sealed pharma factory in Baddi
Airlocks in the Pharma Industry: An essential component
Govt prohibits 14 FDC Drugs, Citing Safety Concerns
USFDA gives approval for Nitisinone capsules
CDSCO gives approval for Tremelimumab combination in India
Gang selling fake medicines busted in Delhi, UP
USFDA warns about safety risks of tailored weight-loss drugs
Line clearance and maintenance in manufacturing: A comprehensive guide
Difference between Validation and Calibration in the Pharma Industry
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
